This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, M. H. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Cohen, M. H. Articles by Pazdur, R.

U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid

Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Correspondence: Martin H. Cohen, M.D., Food and Drug Administration, HFD-150, 5600 Fishers Lane, Rockville, Maryland 20857, USA. Phone: 301-594-2473; Fax: 301-594-0499; e-mail: cohenm{at}cder.fda.gov

The purpose of this report is to summarize information on drugs recently approved by the U.S. Food and Drug Administration. Three drugs have recently been approved: Gleevec^TM (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex^® (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa^® (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. The recommended dose and schedule is 4 mg infused over 15 minutes every 3-4 weeks. These three drugs represent three different types of drug approval: Gleevec is an accelerated approval and supplemental new drug application (NDA); Mesnex tablets represent an oral formulation of a drug approved 14 years ago as an intravenous formulation, and Zometa represents a standard NDA for a noncytotoxic, supportive-care drug. Information provided includes rationale for drug development, study design, efficacy and safety results, and pertinent literature references.

Key Words. Imatinib mesylate • Gastrointestinal stromal tumors • Mesna • Ifosfamide • Zoledronic acid • Bone metastases • Bisphosphonates

This article has been cited by other articles:

				C.-H. Cho, Y. Jun Koh, J. Han, H.-K. Sung, H. Jong Lee, T. Morisada, R. A. Schwendener, R. A. Brekken, G. Kang, Y. Oike, et al. Angiogenic Role of LYVE-1-Positive Macrophages in Adipose Tissue Circ. Res., March 2, 2007; 100(4): e47 - e57. [Abstract] [Full Text] [PDF]

				R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]

				R. E. Brown, M. Lun, J. W. Prichard, T. M. Blasick, and P. L. Zhang Morphoproteomic and Pharmacoproteomic Correlates in Hormone-Receptor-Negative Breast Carcinoma Cell Lines Ann. Clin. Lab. Sci., July 1, 2004; 34(3): 251 - 262. [Abstract] [Full Text] [PDF]